This inventor holds 1 USPTO granted patent. Top assignee: Flow Pharma, Inc.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Tom Hodge and Controlled-Release Antibody Innovation.
Introduction
Tom Hodge is an inventor associated with Flow Pharma, Inc., in Redwood City, California. His patent work concerns controlled delivery of an antibody intended to modulate cytokines and support treatment research involving infections.
Latest Patents
Hodge is named on 1 patent, titled “Controlled Release of Antibodies to Modulate Cytokines.” The invention describes an injectable formulation containing siltuximab encapsulated in poly(lactic-co-glycolic acid), or PLGA, microspheres. The microspheres are designed to release the antibody over hours, days, and weeks, with the polymer’s absorption rate characterized by a specified absorption-rate constant. The patent also describes using siltuximab in treating patients with viral infections, including SARS-CoV-related infections.
Career Highlights
Hodge’s listed patent reflects work on antibody delivery systems that aim to control the timing of therapeutic release. The formulation combines an antibody with a biocompatible, biodegradable polymer carrier.
Collaborations
Hodge is associated with Flow Pharma, Inc. His listed coworker is Scott Burkholtz.
Conclusion
Tom Hodge’s patent focuses on PLGA microspheres for controlled siltuximab release, highlighting an approach to antibody delivery for infection-related treatment research.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile